This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Arrhythmias  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic

Paul S. Chan, MD, MSc; Theodore Chow, MD; Dean Kereiakes, MD; Edward J. Schloss, MD; Theodore Waller, MD; Kim Eagle, MD; Rodney A. Hayward, MD; Sandeep Vijan, MD, MSc

Arch Intern Med. 2006;166:2228-2233.

Background  Implantable cardioverter-defibrillators (ICDs) have been shown in primary prevention efficacy trials to reduce mortality in patients with ischemic heart disease and left ventricular dysfunction. To investigate the generalizabilty of this mortality reduction, we examined the effectiveness of ICDs in clinical practice.

Methods  We developed a prospective multicenter cohort of 770 patients with ischemic left ventricular dysfunction (ejection fraction 35%) and without a history of ventricular arrhythmia, of whom 395 (52%) received ICDs. Mean ± SD follow-up was 27 ± 12 months. We assessed the degree to which ICDs decreased mortality risk using Cox proportional hazards analyses that controlled for clinical predictors of death, receipt of ICD (a propensity score analysis), and predictors of arrhythmic death (including electrophysiologic variables).

Results  Multivariate Cox analyses showed that those with ICDs had significantly lower all-cause mortality (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.33-0.86). This mortality reduction was mediated through dramatically lower arrhythmia-related mortality (HR, 0.35; 95% CI, 0.17-0.73), with no significant effect on cardiovascular nonarrhythmic (HR, 0.81; 95% CI, 0.34-1.96) and noncardiovascular (HR, 0.76; 95% CI, 0.29-2.05) mortality. No differences were found between the ICD and non-ICD groups for a composite outcome of all-cause mortality, appropriate ICD shocks, or documented symptomatic ventricular arrhythmia, which suggests that the 2 groups had similar baseline risk for life-threatening arrhythmic events (HR, 0.96; 95% CI, 0.63-1.45).

Conclusion  In clinical practice, ICDs appear to reduce all-cause and arrhythmic rates of mortality at levels similar to those found in primary prevention trials.

Author Affiliations: Division of Cardiology (Drs Chan and Eagle) and Department of Internal Medicine (Drs Hayward and Vijan), University of Michigan, Ann Arbor; Health Services Research and Development Center for Excellence, Ann Arbor Veterans Affairs Medical Center (Drs Chan, Hayward and Vijan); and Ohio Heart and Vascular Center and The Lindner Clinical Trials Center, Cincinnati (Drs Chow, Kereiakes, Schloss, and Waller).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Implantable cardioverter defibrillators: from evidence of trials to clinical practice
Boriani et al.
Eur Heart J Suppl 2007;9:I66-I73.
ABSTRACT | FULL TEXT  

Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction
Ezekowitz et al.
ANN INTERN MED 2007;147:251-262.
ABSTRACT | FULL TEXT